An Open-Label, Multicentre, Phase 1 Clinical Study to Evaluate the Safety and Efficacy of Zorifertinib Combined With Osimertinib in Patients With Advanced Non-Small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment
Latest Information Update: 03 Feb 2026
At a glance
- Drugs Osimertinib (Primary) ; Zorifertinib (Primary)
- Indications Meningeal carcinomatosis; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Alpha Biopharma
Most Recent Events
- 03 Feb 2026 New trial record